Moderna announces positive phase 1/2 data from mrna-1083, the company's combination vaccine against influenza and covid-19

Mrna-1083 showed strong immunogenicity against influenza and covid-19, with an acceptable reactogenicity and safety profile, compared to licensed standalone vaccines company to begin phase 3 trial of mrna-1083 in adults 50 years and above cambridge, ma / accesswire / october 4, 2023 / moderna, inc. (nasdaq:mrna) today announced positive interim results from the phase 1/2 trial of mrna-1083, an investigational combination vaccine against influenza and covid-19. moderna's investigational combination vaccines are designed to deliver value to individuals, providers and healthcare systems through higher compliance, easier administration and greater convenience.
MRNA Ratings Summary
MRNA Quant Ranking